| Business Summary | | Human
Genome
Sciences
Inc.
is
a
genomics
and
biopharmaceutical
company
focused
on
therapeutic
product
development
and
functional
analysis
of
genes
using
its
proprietary
technology
platform.
The
Company
discovers,
researches,
develops
and
intends
to
commercialize
novel
compounds
for
treating
and
diagnosing
human
disease
based
on
the
identification
and
study
of
genes.
The
Company
focuses
its
internal
product
development
efforts
on
therapeutic
proteins,
antibodies,
peptides
and
fusion
proteins,
and
it
uses
collaborations
for
the
development
of
gene
therapy
products
and
small
molecule
drugs.
It
has
discovered
a
large
number
of
genes
through
its
genomics
capabilities
and
has
developed
a
rapidly
evolving
product
pipeline
based
on
its
discoveries. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | HGSI
is
engaged
in
research
and
development
of
novel
proprietary
pharmaceutical
and
diagnostic
products
based
on
the
discovery
and
understanding
of
the
medical
utility
of
genes.
For
the
six
months
ended
6/30/01,
total
revenues
remained
unchanged
at
$10.5
million.
Net
loss
before
acct.
change
fell
54%
to
$37
million.
Revenues
reflect
continuing
license
fees
and
milestone
payments.
Lower
loss
reflects
lower
debt
conversion
expenses
and
higher
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| William Haseltine, Ph.D., 55 Chairman,
CEO | $656K | -- | Craig Rosen, Ph.D., 42 Exec.
VP of R&D, Director | 469K | $220K | Steven Mayer, 46 Sr.
VP and CFO | 404K | 2.1M | James Davis, Ph.D., 49 Sr.
VP, Gen. Counsel and Sec. | 324K | 1.1M | Susan Bateson McKay, 45 Sr.
VP of HR | -- | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|